Did you know?
You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)
As a follow up to my last post. Perhaps a newly combined company might present a timely opportunity for a NASDAQ listing. As noretreat said and I agree, Abbvie coming in with a BD-2 selective inhibitor does give Apabetalone a credibility boost and good news from either the Zenith or RVX side of a newco along with the commencement of the new kidney trial would all combine for a positive start to a newco. Just some thoughts to ponder.
